Neurofilament-light chain (NfL) as a biomarker of response to higher-efficacy disease-modifying therapies

November 22, 2023

Recommend to a Colleague print

 

Includes data on NfL changes after initiation of fingolimod, ofatumumab, ocrelizumab, natalizumab, alemtuzumab and oral cladribine.

11 slides

Download the slide deck

Recommend to a Colleague

Related Posts

• Ofatumumab 2026 – update on real-world effectiveness
  September 22, 2026
• CLINICAL CASES IN NEUROLOGY – A YOUNG WOMAN WITH MILD EARLY MS
  September 17, 2026
• Anti-CD20 therapy in MS: comparing efficacy and safety
  July 21, 2026
• Highlights of EAN 2026 – Part 2
  July 9, 2026
• Highlights of EAN 2026 – Part 1
  June 30, 2026

Go back to home page